Khalid Qandeel, Rehman Mubashar, Wang Yi-Feng, Liang Xing-Jie
School of Biomedical Engineering & the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, 510260, Guangdong, PR China.
School of Biomedical Engineering & the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, 510260, Guangdong, PR China.
Biochem Biophys Res Commun. 2025 Sep 1;777:152249. doi: 10.1016/j.bbrc.2025.152249. Epub 2025 Jun 25.
Next-generation cancer nanomedicines are revolutionizing therapeutic precision through multifunctional, adaptive, and tumor-specific strategies. This review discusses emerging innovations in cancer nanomedicine, including stimuli-responsive nanomedicines, biomimetic nanomedicines, nanozymes, nanovaccines, immunotherapy, and diagnostic-integrated theranostics. These platforms allow for spatially controlled therapy, deep tumor penetration, and immune reprogramming with minimal systemic toxicity. Although their preclinical performance is promising, several challenges remain, including scalable manufacturing, regulatory validation, and patient-specific optimization. Advances in artificial intelligence-guided design and biomimetic engineering are expected to accelerate clinical translation, positioning these technologies to transform the future of precision oncology.
下一代癌症纳米药物正通过多功能、适应性和肿瘤特异性策略彻底改变治疗的精准度。本综述讨论了癌症纳米医学中的新兴创新，包括刺激响应性纳米药物、仿生纳米药物、纳米酶、纳米疫苗、免疫疗法以及诊断集成型治疗诊断学。这些平台能够实现空间可控治疗、深入肿瘤渗透以及免疫重编程，同时将全身毒性降至最低。尽管它们的临床前表现很有前景，但仍存在一些挑战，包括可扩展制造、监管验证以及针对患者的优化。人工智能引导设计和仿生工程的进展有望加速临床转化，使这些技术能够改变精准肿瘤学的未来。
